Table 6.

Association of Various Cut Points of Amino Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) Cardiovascular Events or Death

	No. of Events/No. at Risk for Cardiovascular Events or Death by Cut Point Position
NT-proBNP Level, pg/mL	Above	Below	Adjusted HR (95% CI)*	P Value
Entire cohort (N = 987)
>50 vs ≤50	241/828	15/150	1.4 (0.7–2.7)	.30
>100 vs ≤100	225/659	31/319	2.2 (1.4–3.6)	.001
>125 vs ≤125	218/594	38/384	2.1 (1.4–3.3)	.007
>150 vs ≤150	205/532	51/446	1.8 (1.2–2.7)	.006
Age <70 y (n = 554)
>50 vs ≤50	89/427	11/127	1.7 (0.7–4.2)	.20
>100 vs ≤100	79/313	21/241	1.7 (0.9–3.4)	.10
>125 vs ≤125	78/275	22/279	2.0 (1.0–3.9)	.04
>150 vs ≤150	74/238	26/316	2.0 (1.0–3.9)	.04
Age ≥70 y (n = 424)
>50 vs ≤50	152/401	4/23	0.9 (0.3–2.7)	.90
>100 vs ≤100	146/346	10/78	3.2 (1.4–7.0)	.004
>125 vs ≤125	140/319	16/105	2.2 (1.2–4.0)	.01
>150 vs ≤150	131/294	25/130	1.6 (0.9–2.7)	.10

Abbreviations: CI, confidence interval; HR, hazard ratio.

^*Adjusted for clinical risk factors (age, sex, history of diabetes, current smoking, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, continuous creatinine clearance), echocardiographic parameters (left ventricular ejection fraction, diastolic dysfunction, left ventricular mass index, inducible ischemia, and treadmill exercise capacity [metabolic equivalents]), serum biomarkers (C-reactive protein concentration and detectable troponin T), and New York Heart Association classification.